GLP-1 weight-loss drugs may extend to children as young as three within two years
Published 12 h ago1 sourceEvidence: Reported
Eli Lilly's Brazilian unit launched a fourth dosage combination under its Mounjaro accessibility program, expanding discounts amid intensifying competition in the obesity and diabetes drug market. The move signals a pricing push to capture share in Brazil's growing GLP-1 segment. Competitive dynamics and regulatory specifics remain partially disclosed.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
Published 12 h ago1 sourceEvidence: Reported
Published 4 h ago3 sourcesEvidence: Reported
Published 13 h ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported